MedTrace Logo

Immune and Viral Outcomes of HIV-1 Therapy Interruption

NCT00051818 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-02-09

No results posted yet for this study

Summary

The purpose of this study is to determine if stopping anti-HIV drugs for a period of time is safe and effective for enhancing the immune function of patients with HIV.

Conditions

  • HIV Infections

Interventions

BEHAVIORAL

Treatment interruption/reinitiation schedule

Sponsors & Collaborators

  • The Wistar Institute

    lead OTHER

Principal Investigators

  • Luis J. Montaner · The Wistar Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2003-05-31
Completion
2003-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00051818 on ClinicalTrials.gov